Non-small cell lung carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Non-small cell lung carcinoma
- Therapeutic area
- Oncology
- non-small cell lung carcinoma
- NSCLC
- NSCLC - non-small cell lung cancer
- non-small cell cancer of lung
- non-small cell cancer of the lung
- non-small cell carcinoma of lung
- non-small cell carcinoma of the lung
- non-small cell lung cancer
- non-small cell lung carcinoma
- non-small cell lung carcinoma (disease)
- Severity
- Severe
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0005233
- Parent condition
- MONDO:0005138
Related records
Broader conditions (20)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Lower respiratory tract disorder
- Lung cancer
- Lung carcinoma
- Lung disorder
- Lung neoplasm
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Respiratory system cancer
- Respiratory system disorder
- Respiratory tract neoplasm
- Thoracic cancer
Narrower conditions (38)
- Acinar lung adenocarcinoma
- Adenosquamous lung carcinoma
- Basaloid large cell lung carcinoma
- Bronchus mucoepidermoid carcinoma
- Classic pulmonary blastoma
- Epithelial predominant pulmonary blastoma
- Fetal lung interstitial tumor
- Large cell carcinoma with rhabdoid phenotype
- Large cell lung carcinoma, clear cell variant
- Lung adenocarcinoma
- Lung adenocarcinoma in situ
- Lung adenoid cystic carcinoma
- Lung colloid adenocarcinoma
- Lung combined large cell neuroendocrine carcinoma
- Lung combined type small cell adenocarcinoma
- Lung giant cell carcinoma
- Lung large cell carcinoma
- Lung occult adenocarcinoma
- Lung occult large cell carcinoma
- Lung pleomorphic carcinoma
Trials (7,651)
- --SuPERIOR Trial--
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- [177Lu]Lu-AKIR001 First-in-human Study
- [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy
- [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.
- [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
- [68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- 125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
- 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
- 131-I-TM-601 Study in Adults With Solid Tumors
- 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Approved drugs (41)
- Adagrasib
- Afatinib dimaleate
- Alectinib hydrochloride
- Amivantamab
- Atezolizumab
- Bevacizumab
- Brigatinib
- Capmatinib hydrochloride
- Ceritinib
- Crizotinib
- Dacomitinib
- Docetaxel
- Docetaxel anhydrous
- Durvalumab
- Entrectinib
- Erlotinib hydrochloride
- Gefitinib
- Gemcitabine hydrochloride
- Ipilimumab
- Lazertinib mesylate
Drugs in development (698)
- [18F]FLUOROMISONIDAZOLE Phase 2
- Abemaciclib Phase 3
- Abequolixron Phase 1
- Abiraterone acetate Phase 1
- Abivertinib Phase 3
- Abivertinib maleate Phase 3
- ABT-510 Phase 2
- ABT-751 Phase 2
- Acalabrutinib Phase 2
- Acapatamab Phase 1
- Acetaminophen Phase 2
- Acetylcarnitine Phase 3
- Acyclovir sodium Phase 2
- Adavosertib Phase 2
- Adebrelimab Phase 2
- Adenosine diphosphate Phase 1
- ADG-106 Phase 1
- AEG-35156 Phase 1
- Afatinib Phase 3
- Aflibercept Phase 1
Other linked drugs (18)
- Anamorelin hydrochloride
- Bafisontamab
- CEP-9722
- Cysteine
- Galunisertib
- Garsorasib
- Iopofosine I 131
- Iruplinalkib
- MP-0250
- Nimesulide
- NM-404 I-124
- Radretumab
- RX-518
- SNX 5422
- Surzebiclimab
- Telisotuzumab adizutecan
- Tulmimetostat
- XMT-1592